Medicare AdvantageCoverageMedium impact
MA08.110d, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.110d for Luspatercept–aamt (Reblozyl®) has been reissued effective December 10, 2025. This is a pharmacy policy update that may affect coverage or authorization requirements for this specialty medication used to treat anemia in certain blood disorders.
Action Required
By December 10, 2025: Billing team should review the updated Luspatercept–aamt (Reblozyl®) policy at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures for Medicare Advantage plans. Update internal protocols accordingly to ensure continued coverage for affected patients.